Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Quell Therapeutics Ltd.. (1/6/22). "Press Release: Quell Therapeutics Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference". London & Boston, MA.

Organisations Organisation Quell Therapeutics Ltd. (QuellTX)
  Organisation 2 Stern Investor Relations Inc. (Stern IR)
  Group Precision Medicine Group (Group)
Products Product J.P. Morgan 40th Annual Healthcare Conference 2022 DIGITAL
  Product 2 regulatory T cell therapy (Tregs)
Person Person Swallow, Mark (Huntsworth 201101 Citigate Dewe Rogerson London Senior Director Life Sciences)

Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually, on Tuesday, January 11, 2022 at 12:00 pm ET.

About Quell Therapeutics

Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.

The Company is leveraging its pioneering phenotype lock technology, unique multi-modular platform and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for stability, persistence and potency than earlier generations of Treg cell therapy approaches.

Quell’s lead candidate QEL-001 is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases.


Luke Henry, Chief Business Officer
Quell Therapeutics

Media: Mark Swallow, Frazer Hall, Eleanor Perkin
MEDiSTRAVA Consulting
+44 203 928 6900

Investors: Christina Tartaglia
Stern Investor Relations, Inc.
+1 212 362 1200

Record changed: 2022-04-27


Picture [iito] Männer Ballett 650x100px

More documents for Quell Therapeutics Ltd. (QuellTX)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Bionnale the Annual Life Sciences Event 650x80px

» top